Last €4.69 EUR
Change Today +0.174 / 3.85%
Volume 0.0
9EY On Other Exchanges
Symbol
Exchange
NASDAQ GS
Berlin
As of 1:58 PM 01/27/15 All times are local (Market data is delayed by at least 15 minutes).

endocyte inc (9EY) Snapshot

Open
€4.55
Previous Close
€4.51
Day High
€4.70
Day Low
€4.40
52 Week High
03/21/14 - €29.05
52 Week Low
10/15/14 - €4.13
Market Cap
195.6M
Average Volume 10 Days
1.4K
EPS TTM
--
Shares Outstanding
41.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ENDOCYTE INC (9EY)

endocyte inc (9EY) Related Businessweek News

No Related Businessweek News Found

endocyte inc (9EY) Details

Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its proprietary technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is primarily developing vintafolide, a SMDC that targets the platinum-resistant ovarian cancer, non-small cell lung cancer, triple negative breast cancer, and carboplatin/paclitaxel combination; and etarfolatide, a proprietary companion imaging agent for vintafolide. The company is also developing product candidates for colorectal, prostate, kidney, endometrial, solid tumors, and other cancers, as well as for chronic inflammatory disorders. The company has a collaboration agreement with Merck Sharp & Dohme Research GmbH for the development and commercialization of vintafolide. Endocyte, Inc. was founded in 1995 and is headquartered in West Lafayette, Indiana.

91 Employees
Last Reported Date: 03/5/14
Founded in 1995

endocyte inc (9EY) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $722.0K
Co-Founder, Chief Scientific Officer and Dire...
Total Annual Compensation: $212.2K
Chief Financial Officer and Chief Operating O...
Total Annual Compensation: $434.4K
Vice President of Clinical Affairs
Total Annual Compensation: $435.6K
Vice President of Research
Total Annual Compensation: $367.8K
Compensation as of Fiscal Year 2013.

endocyte inc (9EY) Key Developments

Endocyte, Inc. Announces Unaudited Financial Results for the Third Quarter Ending Sept. 30, 2014

Endocyte, Inc. announced unaudited financial results for the third quarter ending Sept. 30, 2014. For the quarter, the company reported collaboration revenue of $16,600,000 against $3,904,000 a year ago. Loss from operations was $3,043,000 against $5,778,000 a year ago. Net loss was $3,041,000 or $0.08 per share basic and diluted against $5,675,000 or $0.14 per share basic and diluted a year ago. For the nine months, the company reported collaboration revenue of $47,597,000 against $70,341,000 a year ago. Loss from operations was $15,379,000 against income from operations of $13,213,000 a year ago. Net loss was $15,130,000 or $0.42 per share basic and diluted against net income of $13,540,000 or $0.33 per share diluted a year ago.

Endocyte, Inc., Q3 2014 Earnings Call, Nov 05, 2014

Endocyte, Inc., Q3 2014 Earnings Call, Nov 05, 2014

Endocyte, Inc. Presents at Credit Suisse Annual Healthcare Conference, Nov-11-2014 08:00 AM

Endocyte, Inc. Presents at Credit Suisse Annual Healthcare Conference, Nov-11-2014 08:00 AM. Venue: The Biltmore, 2400 E Missouri Ave, Phoenix, AZ 85016, United States. Speakers: Michael A. Sherman, Chief Financial Officer and Chief Operating Officer.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
9EY:GR €4.69 EUR +0.174

9EY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 9EY.
View Industry Companies
 

Industry Analysis

9EY

Industry Average

Valuation 9EY Industry Range
Price/Earnings 19.5x
Price/Sales 2.5x
Price/Book 1.0x
Price/Cash Flow 20.3x
TEV/Sales 1.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENDOCYTE INC, please visit www.endocyte.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.